Ellsworth Advisors’s Rapport Therapeutics RAPP Stock Holding History

Ellsworth Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-24,539	Closed	-$980K	–	229
2026 Q2	$980K	Buy	+24,539	New	+$902K	0.16%	117

Other funds holding RAPP

CPW

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Ellsworth Advisors's RAPP Position: Q3 2026 in Review

Ellsworth Advisors sold out of Rapport Therapeutics (RAPP) in Q3 2026, closing a stake of 24,539 shares — an estimated $980K sold.

Ellsworth Advisors first reported a position in RAPP in Q2 2026 and held it in 1 quarter. The position peaked at $980K in Q2 2026. 8 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Ellsworth Advisors reported no remaining Rapport Therapeutics position as of Q3 2026 after selling out during the quarter.
Ellsworth Advisors sold 24,539 Rapport Therapeutics shares in Q3 2026, an estimated $980K.
Ellsworth Advisors first reported a position in Rapport Therapeutics in Q2 2026 and held it in 1 quarter.
Ellsworth Advisors's Rapport Therapeutics position peaked at $980K in Q2 2026.
8 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.